CAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORP

Financial Performance:

• The transcript is a strategic overview and does not contain specific Q3 financial metrics (e.g., exact revenue, net income, or profit margins) as the company is a clinical-stage biopharmaceutical entity.
• Cash position stands at $124 million as of the end of Q3, providing sufficient runway through the end of 2028 to reach the SYNGAP1 first-half 2028 data readout.
• Capital allocation is focused on "keeping it tight" to advance clinical programs (CMP-002 for SYNGAP1 and SHANK3) while maintaining operational efficiency.

Guidance and Future Outlook:

• First patients in the SYNGAP1 Phase I/II trial are expected to be dosed by the end of the current year.
• Topline data for the SYNGAP1 program is targeted for the first half of 2028; no interim safety or PK data is anticipated before this date.
• Long-term pipeline expansion includes SHANK3 (Phelan-McDermott syndrome) and undisclosed programs, with a strategy to advance assets indication-by-indication.
• Management projects massive commercial potential for SYNGAP1, citing a patient population of at least 10,000 in the U.S., comparable to major rare disease markets like spinal muscular atrophy and cystic fibrosis.

Business Segments and Product Lines:

• Core Platform: Proprietary antisense oligonucleotide (ASO) technology designed to upregulate gene expression (specifically targeting regulatory RNAs) to treat haploinsufficiency (conditions where one functional allele produces 50% of required protein).
• Lead Program (SYNGAP1): A disease-modifying therapy for SYNGAP1-related disorder, characterized by seizures, cognitive impairment, and neurobehavioral delays; preclinical data in humanized mice and primates demonstrated symptom reversal and gene upregulation.
• Second Program (SHANK3): Focused on Phelan-McDermott syndrome; preclinical data mirrors SYNGAP1, with an estimated 45,000 patients in the U.S.
• Strategic Partnership: Agreement with GSK to identify regulatory RNAs and create ASOs for two large indications (one CNS, one kidney) under a milestone/royalty model; Camp 4 retains CNS assets while GSK advances non-CNS assets.

Market and Competitive Landscape:

• Competitive Advantage: Unique mechanism acting at the transcriptional level ensures all six protein isoforms of SYNGAP1 are produced naturally, unlike gene therapy or splice-switching approaches which may not replicate natural isoform proportions.
• Market Position: Company claims to be the furthest along with a disease-modifying approach for SYNGAP1; the competitive landscape is currently sparse with only academic efforts or early-stage discovery programs downstream of transcription.
• Diagnostic Trends: Diagnostic timelines have improved from a "10-year odyssey" to approximately one year due to whole-genome screening and genetic panels, accelerating patient identification.

Risks and Challenges:

• Regulatory Path: No disease-modifying therapy currently exists for SYNGAP1; regulatory precedent for approval (e.g., accelerated vs. traditional pathways) is being established through ongoing FDA and global regulatory discussions.
• Clinical Success: Phase I/II is a signal-seeking study; success is not guaranteed, and the optimal biological dose is yet to be defined.
• Execution Risks: Site activation and regulatory clearances across four regions (Australia, Argentina, UK, EMA) and the US must be executed sequentially; any delays in patient dosing could impact the 2028 data timeline.

Management Commentary and Tone:

• Tone: Confident, ambitious, and focused on execution; CEO Josh Mandel-Brem emphasizes the "greenfield" nature of gene upregulation and the biological rationality of the approach.
• Valuation: Management views the current stock market cap as "deeply undervalued" relative to the potential of the SYNGAP1 asset and the scalability of the platform once clinical proof-of-concept is achieved.
• Strategy: Emphasis on retaining core CNS assets while leveraging the platform for business development deals to fund operations without diluting equity.

Analyst Questions and Answers:

• Q: Mechanism Specificity: CEO confirmed the platform targets unique regulatory RNAs, preserving built-in genetic specificity without off-target effects on other genes.
• Q: Overexpression Risk: Management stated that the system biologically caps upregulation at two-fold, mitigating risks associated with overshooting protein expression.
• Q: Trial Design: Explained the decision to include a control arm (3:1 randomization) and leverage natural history data (1,400 patient-years) to maintain optionality for regulatory discussions regarding accelerated approval.
• Q: Basket Trials: CEO clarified that due to the genetic specificity of ASOs, the company will pursue indication-by-indication trials rather than basket trials, as each oligo is custom-designed for a specific disease.
• Q: GSK Deal: Confirmed the deal structure involves Camp 4 identifying targets and creating assets, which are then handed off to GSK for further development, generating milestones and royalties.

Other Key Points:

• Delivery Method: Utilizing Gen 2 ASO chemistry (similar to Spinraza) with intrathecal delivery to ensure distribution to critical cortical and hypothalamic regions of the brain.
• Biomarkers: Efficacy assessment will utilize a multi-dimensional approach including EEG signals, actigraphy (sleep), and cognitive metrics (GMFM, Bailey, Vineland) compared against natural history data.
• Platform Scalability: Once the first-in-human success is proven, the platform can move efficiently to new indications as the chemistry and delivery mechanisms are mechanically consistent across diseases.